Pharmacy Participation in Non-Prescription Syringe Sales in Los Angeles and San Francisco Counties, 2007
Tóm tắt
Increasing sterile syringe access for injection drug users (IDUs) is one way to prevent HIV and hepatitis C virus (HCV) transmission in this population. In 2005, California Senate Bill 1159 allowed counties to adopt the Disease Prevention Demonstration Project (DPDP). Where enacted, the DPDP allows pharmacies that register with the county to sell up to ten syringes to adults without a prescription. In the current study, we describe pharmacy participation in nonprescription syringe sales (NPSS) in two counties in California and examine factors associated with NPSS. Telephone and in-person interviews were conducted in Los Angeles (LA) and San Francisco (SF) with 238 pharmacies in 2007 (n = 67 in SF; n = 171 in LA). Quantitative survey items captured pharmacy registration with the county, pharmacy policies/practices, episodes and conditions of NPSS and refusals to sell, potential negative consequences of NPSS, and staff attitudes regarding HIV and HCV prevention for IDUs. Overall, 42% of pharmacies reported NPSS (28% in LA and 81% in SF), although only 34% had registered with the county (17% in LA and 76% in SF). Many pharmacies required proof of a medical condition (80% in LA and 30% in SF) and refused NPSS if the customer was a suspected IDU (74% in LA, 33% in SF). Few negative consequences of NPSS were reported. In multivariate logistic regression analysis, we found that the odds of NPSS were significantly higher among pharmacists who thought syringe access was important for preventing HIV among IDUs [adjusted odds ratio (AOR) = 2.95; 95% confidence interval (CI) = 1.10–7.92], were chain pharmacies (AOR = 12.5; 95% CI = 4.55–33.33), and were located in SF (AOR = 4.88; 95% CI = 1.94–12.28). These results suggest that NPSS were influenced by pharmacists’ perception. NPSS might be increased through greater educational efforts directed at pharmacists, particularly those in non-chain pharmacies.
Tài liệu tham khảo
Armstong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States: 1999 through 2002. Ann Intern Med. 2006;144:705-714.
CDC. HIV prevelance estimates—United States, 2006. MMWR. 2008;57(39):1073-1076.
CDC. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Recomm Rep. 1998;47:1-39.
CDC. New attitudes & strategies: a comprehensive approach to preventing blood-borne infections among IDUs. Atlanta: Centers for Disease Control and Prevention; 2000.
US Public Health Service. HIV Prevention Bulletin: Medical Advice for Persons Who Inject Illicit Drugs. Atlanta, GA: US Department of Health and Human Services; 1997.
Lurie P, Jones TS, Foley J. A sterile syringe for every drug user injection: how many injections take place annually, and how might pharmacists contribute to syringe distribution? J Acquir Immune Defic Syndr. 1998;18(Suppl 1):S45-S51.
Taussig JA, Weinstein B, Burris S, Jones TS. Syringe law and pharmacy regulations are structural constraints on HIV prevention in the U.S. AIDS. 2000;14(Suppl 1):S47-S51.
CDC. Syringe exchange programs—United States, 2005. MMWR Morb Mortal Wkly Rep. 2007;56(44):1164–1167.
Bluthenthal RN, Heinzerling KG, Anderson R, Flynn NM, Kral AH. Approval of syringe exchange programs in California: results from a local approach to HIV prevention. Am J Public Health. 2008;98(2):278–283.
Tempalski B, Friedman R, Keem M, Cooper H, Friedman SR. NIMBY localism and national inequitable exclusion alliances: the case of syringe exchange programs in the United States. Geoforum. 2007;38(6):1250–1263.
Cotten-Oldenburg NU, Carr P, DeBoer JM, Collison EK, Novotny G. Impact of pharmacy-based syringe access on injection practices among injecting drug users in Minnesota, 1998 to 1999. J Acquir Immune Defic Syndr. 2001;27:183–192.
Fuller C, Galea S, Caceres W, Blaney S, Sisco S, Vlahov D. Multilevel community-based intervention to increase access to sterile syringes among injection drug users through pharmacy sales in New York City. Am J Public Health. 2007;97(1):117–124.
Pouget ER, Deren S, Fuller CM, et al. Receptive syringe sharing among injection drug users in Harlem and the Bronx during the New York State expanded syringe access demonstration program. J Acquir Immune Defic Syndr. 2005;39(4):471–477.
Reich W, Compton WM, Horton JC, et al. Pharmacist ambivalence about sale of syringes to injection drug users. J Am Pharm Assoc (Wash). 2002;42(6 Suppl 2):S52–S57.
Diebert R, Goldbaum G, Parker T, et al. Increased access to unrestricted pharmacy sale of syringes in Seattle-King County, Washington: structural and individual level changes. Am J Public Health. 2006;96(8):1347–1353.
Farley TA, Niccolai LM, Billeter M, Kissinger PJ, Grace M. Attitudes and practices of pharmacy managers regarding needle sales to injection drug users. J Am Pharm Assoc (Wash). 1999;39(1):23–26.
Blumenthal W, Springer KW, Jones S, Stark C. Pharmacy student knowledge, attitudes and beliefs about selling syringes to injection drug users. J Am Pharm Assoc. 2002;42(6 (Suppl 2)):S34–S39.
Taussig J, Junge B, Burris S, Jones TS, Sterk CE. Individual and structural influences shaping pharmacists’ decisions to sell syringes to injection drug users in Atlanta, Georgia. J Am Pharm Assoc (Wash). 2002;42(6 Suppl 2):S40–S45.
Stopka T, Garfein R, Ross A, Truax SR. Increasing syringe access and HIV prevention in California: findings from a survey of local health jurisdiction key personnel. J Urban Health. 2007;84(1):116–125.
Epidemiology OoHAa. Key Indicators of Health. Los Angeles: Los Angeles County Department of Public Health; 2007.
Lewis BA, Koester SK, Bush TW. Pharmacists’ attitudes and concerns regarding syringe sales to injection drug users in Denver, Colorado. J Am Pharm Assoc (Wash). 2002;42(6 Suppl 2):S46–S51.
Singer M, Baer HA, Scott G, Horowitz S, Weinstein B. Pharmacy access to syringes among injecting drug users: follow-up findings from Hartford, Connecticut. Public Health Rep. 1998;113(suppl 1):81–89.
Fuller CM, Ahern J, Vadnai L, et al. Impact of increased syringe access: preliminary findings on injection drug user syringe source, disposal, and pharmacy sales in Harlem, New York. J Am Pharm Assoc (Wash). 2002;42(6 Suppl 2):S77–S82.
Rose V. Expanding access to syringes. Focus. 2007;22(3):1–4.
Coffin PO, Ahern J, Dorris S, Stevenson L, Fuller C, Vlahov D. More pharmacists in high-risk neighborhoods of New York City support selling syringes to injection drug users. J Am Pharm Assoc (Wash). 2002;42(6 Suppl 2):S62–S67.
Finkelstein R, Tiger R, Greenwald R, Mukherjee R. Pharmacy syringe sale practices during the first year of expanded syringe availability in New York City (2001–2002). J Am Pharm Assoc (Wash). 2002;42(6 Suppl 2):S83–S87.